Observation on the Therapeutic Effect of Lymphocyte Immunotherapy for Repeated Biochemical Pregnancy Loss

Abstract

Objective: To investigate the clinical effect of lymphocyte immunotherapy for women with repeated biochemical pregnancy loss. Methods: A retrospective study was conducted from January 2015 to January 2016, involving 100 patients with repeated biochemical pregnancy loss as observation subjects. After enrollment, patients were divided into two groups (50 patients in each group) according to different treatment regimens. The observation group received conventional tocolysis combined with lymphocyte immunotherapy, while the control group only received conventional tocolysis treatment. The pregnancy outcome, improvement of serum factor levels, and treatment safety were evaluated to compare the clinical effects of different treatment regimens. Results: The pregnancy success rate was 82.00% in the observation group and 48.00% in the control group (χ² = 12.7033, P < 0.05). After treatment, the interferon-y (IFN-y) level in the observation group was higher than that in the control group, while the interleukin-8 (IL-8) and regulated upon activation, normal T-cell expressed and secreted (RANTES) levels were lower than those in the control group (P < 0.05). There was no significant difference in treatment safety between the two groups (P > 0.05). Conclusion: The introduction of lymphocyte immunotherapy in patients with repeated biochemical pregnancy loss can improve the success rate of pregnancy and has a significant therapeutic effect, which is worthy of application.